ClinicalTrials.gg
RecruitingNCT07688187Updated Sep 18, 2026

A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma

A Phase 1 interventional study of PD-32766D (a Copper-64 [64Cu] labeled peptide) and PD-32766T (an Actinium-225 [225Ac] labeled peptide) in Clear Cell Renal Cell Carcinoma, sponsored by PeptiDream Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by PeptiDream Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,142 studies in Carcinoma, Renal Cell with a site in United States — 156 open to participants now, 280 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Planned enrollment
374th of 1,008
60 · median 40
Started
2026
with 42 others
Phase 1
342 of 1,142
38 open now
Primary completion
2029-05
later than 237 of 278 live
Registered
1,132nd of 1,142
by date

Among the 1,142 studies in Carcinoma, Renal Cell with a site in United States, this one is the 374th largest by planned enrollment of the 1,008 interventional ones that give a count, is one of 43 that started in 2026, is one of 342 in phase 1, reaches primary completion later than 237 of the 278 other live ones, and was the 1,132nd registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

156 of the 1,142 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

150 more — sign in →

All 156 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,142 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multicenter, Phase 1a/1b study evaluating the theranostic pair 64Cu-PD-32766 Injection (PD-32766D) and 225Ac-PD-32766 Injection (PD-32766T) in adult patients with relapsed or refractory Carbonic Anhydrase IX (CA9)-expressing clear cell renal cell carcinoma (ccRCC). The primary objective is to evaluate the safety and tolerability of PD-32766T, and to characterize its pharmacokinetics and preliminary antitumor activity.

Participants will first undergo imaging with PD-32766D to assess CA9 expression. Subjects with positive tumor uptake will be eligible to receive PD-32766T. In Phase 1a, PD-32766T will be administered in an escalating dose levels and schedule determined according to protocol and Safety Review Committee recommendations.

In Phase 1b, participants will receive PD-32766T at the recommended dose and schedule identified from Phase 1a to further evaluate safety, tolerability, and preliminary efficacy.

A total of up to 60 participants will be enrolled in the study.

03

Conditions studied

  • Clear Cell Renal Cell Carcinoma

Keywords

  • ccRCC
  • Renal Cell Carcinoma (Kidney Cancer)
  • Renal Cell Carcinoma (RCC)
  • CA9
  • Actinium
  • Copper
  • Theranostics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged ≥18 years.
  2. Participants with confirmed diagnosis of ccRCC will be included based on the following characteristics:

    • Histological confirmed locally advanced, unresectable, or ccRCC, after all available standard therapy.
    • Presence of evaluable disease by (RECIST) guideline (defined by RECIST v1.1).
  3. Presence of positive tumor uptake
  4. (ECOG) performance status (PS) of 0 to 1.
  5. The participant's with adequate organ function
  6. of at least 12 weeks as assessed by the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Concurrent serious (as determined by the Investigator), uncontrolled medical conditions, or life-threatening or other significant comorbid conditions.
  2. Any chemotherapy, radiotherapy, immunotherapy, major surgery, biologic, or hormonal therapy for treatment of solid tumors within 28 days.
  3. Participants who have not had resolution of toxic effects of prior systemic cancer therapy, surgery, or radiotherapy.
  4. Administration of a radiopharmaceutical with therapeutic intent within a period of 6 months.
  5. Any previous CA9 targeting treatment.
  6. Known to the active substance or to any of the of the PD-32766D and or T.
  7. Clinically unstable CNS tumor at the time of screening.
  8. History of bowel perforation or bowel infarction, history of active stomach or duodenum ulcer or fistula in the last 2 years, history of gastroesophageal reflux disease or enterocolitis Grade ≥3 according to and/or known active gastrointestinal infection, any unresolved prior radiation-induced gastrointestinal injury.
  9. Acute infection requiring IV antibiotics, antivirals, or antifungals within 14 days prior to the initiation of treatment (oral treatment are allowed).
  10. Pregnant or breastfeeding women.
  11. Known active infection with (HIV), virus (HCV), or virus (HBV).
  12. Have been diagnosed with another primary .
  13. Have significant, uncontrolled, or active cardiovascular disease
  14. Bladder outflow obstruction or unmanageable urinary incontinence.
  15. Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
  16. Any major surgery within 12 weeks before enrolment.
  17. History of psychiatric illness or social situations likely to interfere with ability to comply with protocol required assessment or give .
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Phase 1a Dose Escalation

    PD-32766D is administered for imaging and then, subjects with positive tumor uptake will receive PD-32766T in recommended dose levels and schedule according Safety Review Committee.

    Drug: PD-32766D (a Copper-64 [64Cu] labeled peptide) · Drug: PD-32766T (an Actinium-225 [225Ac] labeled peptide)

  • Experimental
    Phase 1b Dose Expansion

    Subjects will receive PD-32766T in recommended dose levels and schedule.

    Drug: PD-32766D (a Copper-64 [64Cu] labeled peptide) · Drug: PD-32766T (an Actinium-225 [225Ac] labeled peptide)

Interventions

06

What researchers measure

Primary outcomes

  1. Number and proportion of participants who experience at least 1 dose-limiting toxicities (DLTs).

    Number of participants with DLT and DLT rate

    Time frame: Through completion of DLT evaluation (6weeks)

  2. Incidence, intensity, seriousness, and causality of adverse events (AEs), treatment-emergent adverse events (TEAEs), adverse event of special interest (AESI) and serious adverse events (SAEs).

    Number and proportion of participants with AEs, TEAEs, AESI and SAEs.

    Time frame: Through study completion, an average of 6 months.

  3. Incidence of TEAEs leading to dose delay, dose interruption, dose reduction, and/or discontinuation.

    Number and proportion of participants with TEAEs leading to dose delay, dose interruption, dose reduction, and/or discontinuation as a measure of tolerability.

    Time frame: Through study completion. an average of 6 months

  4. Maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of PD-32766T based on dose-limiting toxicities.

    MTD and RDE are determined based on the occurrence of DLTs during the DLT evaluation period.

    Time frame: Through completion of DLT evaluation (6weeks).

Secondary outcomes

  1. Area under the plasma concentration-time curve (AUC) of PD-32766T

    Pharmacokinetic (PK) parameters based on radioactivity in the blood following the first dose administration of PD-32766T

    Time frame: Through completion of 6 cycles (each cycle is 4 or 6 weeks)

  2. Maximum observed concentration (Cmax) of PD-32766T

    Pharmacokinetic (PK) parameters based on radioactivity in the blood following the first dose administration of PD-32766T

    Time frame: Through completion of 6 cycles (each cycle is 4 or 6 weeks)

  3. Urine PK profile of PD-32766T after IV injection

    Radioactivity in the urine following the first dose administration: amount, cumulative amount, and fraction of the dosed radioactivity excreted in urine (Fe).

    Time frame: Through completion of 6 cycles (each cycle is 4 or 6 weeks)

  4. Objective response rate (ORR), Disease control rate (DCR) and Duration of response (DoR) according to RECIST v1.1

    Time frame: Through study completion, an average 6 months.

07

Study locations

1 of 1 sites recruiting
  • Research site
    Omaha, Nebraska 68130, United States
    Recruiting
    • Site Contact · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2029, 34 months after the start.

Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 34 months is below that.

Counting every sponsor, half of 220 studies reached it within 50 months; a quarter within 32 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jul 7, 2026
StartActual
Jul 7, 2026
Primary completionEst.
May 2029
CompletionEst.
Jun 2029
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07688187
Lead sponsor
PeptiDream Inc.
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
Jul 7, 2026
Primary completion
May 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Sep 18, 2026

Study contacts

Clinical Lead
Contact
PD_CA9_clinical@peptidream.com
044-270-1300

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Actinium-225

Start the discussion